MW 432.5 Da, Purity >99%. γ-Secretase inhibitor. Inhibits Notch signalling in vitro. Inhibits total Aβ and Aβ42 production in human primary cultures (IC50 values are 115 and 200 nM, respectively) with no effect on APPα and APPβ levels. Blood-brain barrier permeable. 3D Growth matrix component and component of cerebral organoid differentiation media.
6530402N02Rik, AD3, AD3L, AD3LP, AD4, AD5, AL138795.3, APH 2, APH1A gamma secretase subunit, APH1A_HUMAN, ATAG1874, Ad3h, Alzheimer disease 4, Anterior Pharynx Defective 1, Anterior pharynx defective 1 homolog A, Anterior pharynx defective 2, Aph-1alpha, CGI 78, CMD1V, E5-1, FAD, Gamma Secretase Subunit PEN2, Gamma-secretase subunit APH-1A, Gamma-secretase subunit PEN-2, Hematopoietic stem/progenitor cells protein MDS033, Homo Sapiens Clone CC44 Senilin 1, KIAA0253, Likely ortholog of C. elegans anterior pharynx defective 1A, MDS033, MSTP064, NCT, NICA_HUMAN, Ncstn, Nicastrin, OTTHUMP00000035671, OTTHUMP00000035672, OTTHUMP00000228286, OTTHUMP00000228288, PEN2_HUMAN, PS-1, PS-2, PS1-CTF12, PSEN1, PSEN2, PSF, PSN1_HUMAN, PSN2_HUMAN, PSNL1, PSNL2, Presenilin 2, Presenilin 2 (Alzheimer disease 4), Presenilin Enhancer 2, Presenilin enhancer 2 homolog, Presenilin enhancer protein 2, Presenilin-1 CTF12, Presenilin-2 CTF subunit, Presenilin-stabilization factor, Protein S182, RP11 517F10.1, RP11517F101, S182, STM-2, UNQ579/PRO1141, psenen
MW 432.5 Da, Purity >99%. γ-Secretase inhibitor. Inhibits Notch signalling in vitro. Inhibits total Aβ and Aβ42 production in human primary cultures (IC50 values are 115 and 200 nM, respectively) with no effect on APPα and APPβ levels. Blood-brain barrier permeable. 3D Growth matrix component and component of cerebral organoid differentiation media.
γ-Secretase inhibitor. Inhibits Notch signalling in vitro. Inhibits total Aβ and Aβ42 production in human primary cultures (IC50 values are 115 and 200 nM, respectively) with no effect on APPα and APPβ levels. Blood-brain barrier permeable. 3D Growth matrix component and component of cerebral organoid differentiation media.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
2D chemical structure image of ab120633, DAPT, gamma-Secretase inhibitor
Anti-AKT1 (phospho S473) antibody [EP2109Y] ab81283 staining AKT1 (phospho S473) in MCF7 cells treated with DAPT (ab120633), by ICC/IF. Decrease in expression of AKT1 (phospho S473) correlates with increased concentration of DAPT, as described in literature.
The cells were incubated at 37°C for 24h in media containing different concentrations of ab120633 (DAPT) in DMSO, fixed with 4% formaldehyde for 10 minutes at room temperature and blocked with PBS containing 10% goat serum, 0.3 M glycine, 1% BSA and 0.1% tween for 2h at room temperature. Staining of the treated cells with Anti-AKT1 (phospho S473) antibody [EP2109Y] ab81283 (1/200 dilution) was performed overnight at 4°C in PBS containing 1% BSA and 0.1% tween. A DyLight 488 goat anti-rabbit polyclonal antibody (Goat Anti-Rabbit IgG H&L (DyLight® 488) preadsorbed ab96899) at 1/250 dilution was used as the secondary antibody. Nuclei were counterstained with DAPI and are shown in blue.
Kc167 cells were treated with varying concentrations of DAPT (ab120633) in DMSO for 16hr at 25°C; DMSO only was used as the negative control. The cells were further incubated for 30 minutes with 4mM EGTA in PBS (in the presence of DAPT), and were then lysed for analysis. To measure Notch activity, Notch targets E(spl)mβ-HLH and E(spl)m3-HLH mRNA levels were assayed. Data shows the fold change of mRNA levels of E(spl)mβ-HLH and E(spl)m3-HLH under different conditions, normalised to DMSO treatment (negative control). Notch activation by EGTA is abrogated by treatment with DAPT.
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com